Chemotherapy-induced Nausea and Vomiting
📧 Sign up to get email alerts when something new happens for Chemotherapy-induced Nausea and Vomiting.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2023-08-14FDA Approved: PALONOSETRON HYDROCHLORIDE — Original Application (Meitheal Pharmaceuticals Inc.)
FDA approved Meitheal Pharmaceuticals' palonosetron hydrochloride generic under an Original Application for preventing postoperative nausea …
-
CLINICAL_TRIALS trial_result · 2023-08-01Clinical Trial Update: Effect of Inhaled Aromatherapy on Chemo-Induced Nausea Vomiting (NCVI): CINVAROM (Chemotherapy Induced Nausea Vomiting and AROMatherapy) [Phase 2]
Phase 2 clinical trial evaluating inhaled aromatherapy for chemotherapy-induced nausea and vomiting (CINV) called CINVAROM; the study is com…
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: Safety Study of Repeat Doses of SUSTOL in Adults [Phase 4]
Phase 4 safety study assessing repeat dosing of SUSTOL in adults with chemotherapy-induced nausea and vomiting.
-
FDA approval · 2023-07-25FDA Approved: FOSAPREPITANT DIMEGLUMINE — Supplemental Application (Hikma Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Fosaprepitant Dimeglumine from Hikma Pharmaceuticals USA Inc. under the ANDA program. The submis…
-
FDA approval · 2023-05-25FDA Approved: SUSTOL — Supplemental Application (Heron Therapeutics, Inc.)
FDA approved a supplemental application for SUSTOL (granisetron) from Heron Therapeutics, Inc. The action concerns regulatory approval relat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-05-24FDA Approved: ONDANSETRON — Supplemental Application (Accord Healthcare, Inc.)
FDA approved a supplemental application for Ondansetron, manufactured by Accord Healthcare, Inc., signaling an update to its regulatory stat…
-
CLINICAL_TRIALS trial_result · 2023-05-09Clinical Trial Update: Olanzapine for Nausea/Vomiting Prophylaxis in Recipients of Hematopoietic Stem Cell Transplants [Phase 3]
Phase 3 trial assessing olanzapine for nausea and vomiting prophylaxis in recipients of hematopoietic stem cell transplants has completed wi…
-
CLINICAL_TRIALS trial_result · 2023-05-03Clinical Trial Update: Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer [Phase 4]
Phase 4 trial comparing intravenous versus oral 5-HT3 antagonists combined with NK-1 receptor antagonists for prevention of chemotherapy-ind…
-
FDA approval · 2023-05-01FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
The FDA approved a supplemental application for ondansetron hydrochloride from Onesource Specialty Pharma Limited, approving this generic an…
-
FDA approval · 2023-05-01FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Onesource Specialty Pharma Limited)
FDA approved a supplemental application for ondansetron hydrochloride submitted by Onesource Specialty Pharma Limited (ANDA 078257). This ac…
-
FDA approval · 2023-04-26FDA Approved: ONDANSETRON — Supplemental Application (West-Ward Pharmaceuticals Corp)
FDA approved a supplemental application for ondansetron submitted by West-Ward Pharmaceuticals Corp, indicating an approved change to an exi…
-
FDA approval · 2023-04-14FDA Approved: FOSAPREPITANT — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for fosaprepitant dimeglumine from NorthStar RxLLC.
-
CLINICAL_TRIALS trial_result · 2023-04-12Clinical Trial Update: A Randomized Controlled Trial of SP-01 (Granisetron Transdermal Delivery System) in Chemotherapy-induced Nausea and Vomiting [Phase 3]
Phase 3 randomized trial of SP-01 Granisetron Transdermal Delivery System for chemotherapy-induced nausea and vomiting has been completed.
-
FDA label_change · 2023-02-15FDA Approved: AKYNZEO — Supplemental Application (Helsinn Therapeutics (U.S.), Inc.)
FDA approved a supplemental application for AKYNZEO (fosnetupitant and palonosetron) to update the labeling for prevention of chemotherapy-i…
-
CLINICAL_TRIALS trial_result · 2023-02-08Clinical Trial Update: Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy [Phase 3]
Phase 3 clinical trial evaluating aprepitant triple therapy to prevent chemotherapy-induced nausea and vomiting in nondrinking and young wom…
-
CLINICAL_TRIALS trial_result · 2023-01-20Clinical Trial Update: Buccal Film vs IV Palonosetron for Prevention of CINV in Cancer Patients Receiving MEC [Phase 3]
Phase 3 trial comparing Buccal Film to IV Palonosetron for prevention of chemotherapy-induced nausea and vomiting in cancer patients receivi…
-
FDA approval · 2022-12-06FDA Approved: SANCUSO — Supplemental Application (Cumberland Pharmaceuticals Inc.)
FDA approved Cumberland Pharmaceuticals' Supplemental Application for SANCUSO (granisetron), marking an updated approval for this antiemetic…
-
FDA approval · 2022-11-09FDA Approved: ONDANSETRON HYDROCHLORIDE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
The FDA approved a supplemental application for ondansetron hydrochloride from Sun Pharmaceutical Industries, Inc., under an ANDA. This docu…
-
FDA approval · 2022-11-09FDA Approved: ONDANSETRON — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approves Sun Pharmaceutical Industries' supplemental application for ondansetron, an antiemetic. The approval indicates a change to the …
-
FDA approval · 2022-09-21FDA Approved: DRONABINOL — Supplemental Application (Wellhouse Pharma, LLC)
FDA approved a supplemental application for dronabinol submitted by Wellhouse Pharma, LLC.
-
FDA approval · 2022-09-16FDA Approved: APONVIE — Original Application (Heron Therapeutics, Inc.)
The FDA approved APONVIE, an intravenous formulation of aprepitant from Heron Therapeutics, under an original drug application for the preve…
-
FDA approval · 2022-08-22FDA Approved: GRANISETRON HYDROCHLORIDE — Supplemental Application (Natco Pharma Limited)
FDA approves a supplemental application for granisetron hydrochloride from Natco Pharma Limited.
-
FDA approval · 2022-08-12FDA Approved: APREPITANT — Supplemental Application (Golden State Medical Supply, Inc.)
FDA approved a supplemental application for APREPITANT from Golden State Medical Supply, Inc., under an ANDA.
-
CLINICAL_TRIALS trial_result · 2022-07-29Clinical Trial Update: Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV [Phase 3]
A Phase 3 trial evaluating olanzapine or dexamethasone, with a 5-HT3 receptor antagonist and an NK-1 receptor antagonist, for preventing che…
-
CLINICAL_TRIALS trial_result · 2022-07-28Clinical Trial Update: Low Dose Olanzapine to the Prophylaxis of Nausea and Vomiting Induced by Chemotherapy in Children and Adolescents [Phase 3]
A Phase 3 clinical trial evaluating low-dose olanzapine for preventing chemotherapy-induced nausea and vomiting in children and adolescents.